Celldex Therapeutics, Inc (CLDX) Monday reported positive preclinical data for CDX-622, a bispecific antibody targeting inflammation and fibrosis through dual inhibition of thymic stromal lymphopoietin and mast cell depletion via stem cell factor starvation.
The data showed that CDX-622 effectively neutralizes both targets, reducing tissue mast cells and Type 2 inflammatory responses, suggesting potential benefits over single-target therapies.
Presented at the AAAAI Annual Meeting, the findings support the ongoing Phase 1 study in healthy volunteers, which began in November and is actively enrolling. Celldex plans to share initial clinical data later this year.
CLDX is currently trading at $20.96 up 1.90 percent or $0.39 on the Nasdaq.
For comments and feedback: editorial@rttnews.com